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Platelet rich plasma injection for acute Achilles tendon rupture: 
PATH-2 randomised, placebo controlled, superiority trial
David J Keene,1 Joseph Alsousou,2 Paul Harrison,3 Philippa Hulley,4 Susan Wagland,1  
Scott R Parsons,1 Jacqueline Y Thompson,1 Heather M O’Connor,5 Michael Maia Schlüssel,5 
Susan J Dutton,5 Sarah E Lamb,1,5 Keith Willett,1 on behalf of the PATH-2 trial group
AbstrAct
Objective
To determine whether an injection of platelet rich 
plasma improves outcomes after acute Achilles 
tendon rupture.
Design
Randomised, placebo controlled, two arm, parallel 
group, participant and assessor masked, superiority 
trial.
setting
Secondary care trauma units across 19 hospitals in 
the United Kingdom’s health service.
ParticiPants
Recruitment commenced in July 2015 and follow-up 
was completed in March 2018. 230 adults aged 18 
years and over were included, with acute Achilles 
tendon rupture presenting within 12 days of injury 
and managed with non-surgical treatment. Exclusions 
were injury at the insertion or musculotendinous 
junction, major leg injury or deformity, diabetes 
mellitus, platelet or haematological disorder, systemic 
corticosteroids, anticoagulation treatment, and other 
contraindicating conditions.
interventiOns
Participants were randomised 1:1 to platelet rich 
plasma (n=114) or placebo (dry needle; n=116) 
injection. All participants received standard 
rehabilitation care (ankle immobilisation followed by 
physiotherapy).
Main OutcOMes anD Measures
Primary outcome was muscle tendon function at 24 
weeks, measured objectively with the limb symmetry 
index (injured/uninjured×100) in maximal work done 
during the heel rise endurance test (an instrumented 
measure of repeated single leg heel rises until 
fatigue). Secondary outcomes included patient 
reported function (Achilles tendon rupture score), 
quality of life (short form 12 version 2®), pain (visual 
analogue scale), goal attainment (patient specific 
functional scale), and adverse events. A central 
laboratory analysed the quality and content of platelet 
rich plasma. Analyses were by modified intention to 
treat.
results
Participants were 46 years old on average, and 57 
(25%) of 230 were female. At 24 weeks, 202 (88%) 
participants completed the heel rise endurance 
test and 216 (94%) the patient reported outcomes. 
The platelet rich plasma was of good quality, with 
expected growth factor content. No difference 
was detected in muscle tendon function between 
participants receiving platelet rich plasma injections 
and those receiving placebo injections (limb symmetry 
index, mean 34.7% (standard deviation 17.7%) v 
38.5% (22.8%); adjusted mean difference −3.9% 
(95% confidence interval −10.5% to 2.7%)) or in any 
secondary outcomes or adverse event rates. Complier 
average causal effect analyses gave similar findings.
cOnclusiOns
There is no evidence to indicate that injections of 
platelet rich plasma can improve objective muscle 
tendon function, patient reported function, or quality 
of life after acute Achilles tendon rupture compared 
with placebo, or that they offer any patient benefit.
trial registratiOn
ISRCTN54992179.
Introduction
The most commonly ruptured tendon is the Achilles, 
and the incidence is rising.1 2 After Achilles tendon 
rupture, patients experience limitations in tendon 
loading activities, resulting in work incapacity and 
many months off sport.3 4 Accelerating recovery and 
improving quality of the tissue repair are therefore 
desirable.
Platelet rich plasma is an autologous, whole 
blood product that provides a supraphysiological 
concentration of platelets, leucocytes, growth factors, 
and other bioactive proteins such as cytokines 
and chemokines for delivery to an injury site.5 As 
platelet rich plasma has shown positive cellular 
and physiological effects on tendon healing under 
laboratory conditions in most studies,6 it is now 
used extensively in sports and musculoskeletal 
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WhAt Is AlreAdy knoWn on thIs topIc
After Achilles tendon rupture, patients experience limitations in activities that 
load the tendon, resulting in work incapacity and many months off sport and 
work; accelerating recovery and improving quality of the tissue repair is therefore 
desirable
Autologous platelet rich plasma containing supraphysiological platelet 
concentrations from whole blood is used extensively in musculoskeletal 
medicine
Although platelet rich plasma positively affects cellular and physiological tendon 
healing under laboratory conditions, quality of clinical efficacy evidence is poor
WhAt thIs study Adds
There is no evidence to indicate that injections of platelet rich plasma improve 
objective muscle tendon function, patient reported function, or quality of life 
after acute Achilles tendon rupture compared with placebo, or that they offer any 
patient benefit
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orthopaedic medicine, with the market projected to 
be worth US$383.56m (£297.20m; €344.49m) by 
2023.7 Its popularity has been fuelled by much media 
attention following its use by elite athletes.8 However, 
commercial preparation systems of platelet rich plasma 
only have US Food and Drug Administration approval 
based on device performance and safety, not clinical 
efficacy.9 Despite 37 clinical trials on applications of 
platelet rich plasma in musculoskeletal injuries so far, 
its efficacy remains uncertain.10 11 These trials, and the 
two previous trials of platelet rich plasma in Achilles 
rupture,12 13 are hampered by a lack of standardisation 
of platelet rich plasma preparations and quality 
control, underpowered studies, and potential con­
founders such as concurrent surgery.14
The Achilles tendon rupture offers an optimal 
clinical model for determining the efficacy of platelet 
rich plasma because it has a relatively homogenous 
presentation, and is easy to diagnose and mechanically 
test, compared with other tendon rupture sites. 
We aimed to determine the clinical efficacy of a 
standardised preparation of platelet rich plasma in 
treating acute, non­surgically managed rupture of the 
Achilles tendon in a randomised controlled trial. We 
hypothesised that if platelet rich plasma accelerated 
tendon healing and improved mechanical properties of 
the healing tissue, it would result in improved muscle 
tendon function of participants.
Methods
study design and eligibility criteria
PATH­2 was a randomised, placebo controlled, multi­
centre, two arm, parallel group, superiority trial 
with masked participants and outcome assessors 
conducted at 19 hospitals in the United Kingdom. The 
trial methods, interventions, and analysis plan have 
been published.15 16
Participants
We included adults who were aged 18 and over; had 
a clinical diagnosis (with or without confirmatory 
diagnostic imaging) of a complete acute mid­substance 
rupture of the Achilles tendon made by the treating 
clinician in the outpatient orthopaedic trauma clinic; 
were within 12 days of injury; were able to walk unaided 
pre­injury; and were being managed non­surgically by 
immobilising the ankle in a cast, splint, or boot. We 
excluded those individuals clinically diagnosed with a 
tendon rupture at the insertion or musculotendinous 
junction, previous major leg injury or deformity, 
diabetes mellitus, platelet or haematological disorder, 
current systemic corticosteroids, treatment doses of 
anticoagulation treatment, and other contraindicating 
conditions (lower limb gangrene/ulcers, peripheral 
vessel disease, hepatic or renal failure or dialysis, 
pregnant or breast feeding, radiation or chemotherapy 
in previous three months, inadequate venous access). 
In May 2016, nine months into recruitment, the 
eligibility criteria were amended (see supplementary 
file for details on all protocol amendments). A key 
change was an extension of the maximum number 
of days since injury, from seven to 12 days. During 
the initial months of screening, we noted that most 
patients were arriving at clinics within 12 days for 
acute treatment, which meant that many patients in 
the target population were not being offered entry to 
the study. All participants provided written informed 
consent.
randomisation
Following consent and baseline assessments, partici­
pants were individually randomised 1:1 to an injection 
of platelet rich plasma or placebo via a central 24 
hour, web based, randomisation allocation system 
developed and provided by the Oxford Clinical Trials 
Research Unit. Initial randomisation was done in 
variable permuted blocks stratified by study site and 
age group (<55 v ≥55 years). However, the age groups 
had not been implemented, owing to a technical issue, 
which led to an imbalance of treatment across age 
groups. To provide balance at the end of the study 
over stratification factors, the system was changed 
to minimisation using the existing randomised 
participants, including a probabilistic element (0.8) 
to prevent predictability of treatment allocation. 
Minimisation factors were study site and age group 
as originally intended.17 These amendments were 
approved by the trial steering, data monitoring, and 
ethics committees.
interventions
Participants from both groups attended the centres 
within 12 days of injury to have blood withdrawn and 
receive an injection in the tendon gap during one visit. 
Participants randomly assigned to receive platelet 
rich plasma had 55 mL of venous blood withdrawn. 
From this volume, 5 mL was used for whole blood 
analysis and 50 mL was used to produce 8 mL of 
leucocyte and platelet rich plasma using the same 
model of specialised automated centrifuge (MAG 200 
MAGELLAN Autologous Platelet Separator, Arteriocyte 
Medical Systems, MA) and sterile disposable kit (MDK 
300/300­1, Arteriocyte Medical Systems, MA) in all 
centres. Participants in the placebo group still had 
5 mL of venous blood withdrawn that was used for 
whole blood analysis. Participants from both groups 
waited for about 17 minutes after blood withdrawal 
before receiving the injection (time taken to prepare 
the platelet rich plasma).
For both interventions, participants lay face down 
on a treatment table. The treating surgeon or specialist 
physiotherapist palpated the tendon gap to identify 
the injection site. Use of imaging was not necessitated 
by the trial protocol. The clinician cleaned the site, 
injected a local anaesthetic (1­2 mL) into the skin, 
and then injected the intervention in the centre of the 
tendon gap. The platelet rich plasma group had 4 mL 
of platelet rich plasma injected. The remaining 4 mL 
of platelet rich plasma was processed for laboratory 
analysis and quality control. The placebo group had 
the same sized needle attached to an empty syringe 
inserted into the tendon gap, held in place for the 
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duration of a platelet rich plasma injection, and 
withdrawn without injecting anything. All treating 
clinicians undertook study specific training, used a 
step­by­step preparation manual, and had access to a 
training video.
After injection, participants continued with usual 
local non­surgical care for a ruptured Achilles tendon 
including local protocols for venous thromboembolism 
prophylaxis, except that we standardised the reha­
bilitation protocol to reduce substantial variations 
between groups and recruiting hospitals. The ankle 
was initially immobilised in an equinus position for at 
least three weeks after the intervention. Clinicians were 
instructed to avoid participants’ having full time ankle 
immobilisation or non­weight bearing for longer than six 
weeks. All participants were referred to a physiotherapist 
for supervised rehabilitation. Adherence to rehabilitation 
protocol was monitored in the participant reported 
questionnaires at 4, 7, and 13 weeks.
The whole blood and platelet rich plasma samples 
were analysed in a central laboratory at the Institute of 
Inflammation and Ageing, University of Birmingham, 
Birmingham, UK. Whole blood and platelet rich 
plasma cell counts were determined by a Sysmex 
XN­1000 Haematology analyser (Sysmex UK, Milton 
Keynes, UK). The instrument provides three different 
platelet counts; impedance, optical, and fluorescent. 
Where possible, the fluorescent platelet count was the 
preferred platelet count used. Instrument performance 
was checked internally daily (XN Check) and externally 
monthly (UKNEQAS, Watford, UK)18 to ensure quality 
and accuracy. Platelet quality within fixed resting 
and activated samples (PAMfix, Platelet Solutions, 
Nottingham, UK) was analysed by measuring the 
expression of P selectin (CD62p), a platelet specific 
activation marker, by flow cytometry (Accuri Flow 
cytometer, Becton Dickinson, Oxford, UK). Growth 
factor concentrations (of platelet derived growth 
factor­AB, insulin­like growth factor 1, vascular 
endothelial growth factor, fibroblast growth factor­
basic, and transforming growth factor β1) within the 
platelet rich plasma were measured by enzyme linked 
immunosorbent assay (see supplementary file for 
further sample preparation information).
Masking
All participants were informed that up to 55 mL of 
venous blood would be taken, but the exact amounts 
for each intervention were not disclosed. It was agreed 
with the ethics committee that the protocol and patient 
information sheet would only contain the maximum 
volume of blood to be taken. In practice, differing 
volumes of blood were taken because it was deemed 
unacceptable to take more blood than required for 
study participation and treatment. Injections were 
prepared out of participants’ sight while they waited. 
A dummy spin cycle was activated for the placebo 
group if the platelet rich plasma centrifuge was within 
audible range. Participants received the injection 
lying face down with instructions not to turn to view 
the procedure or injection syringes. Primary outcome 
assessors were not aware of allocation or treatment. 
Clinicians involved in preparing or delivering the 
intervention could not be masked. We trained all staff 
involved in preparation and delivery and provided a 
comprehensive manual with step­by­step instructions 
to facilitate masking. It was emphasised that the 
intervention should not be discussed with participants.
Outcomes and study assessments
The primary outcome time point was 24 weeks, when 
participants attended an appointment to complete self 
report questionnaires on secondary outcome measures 
and a clinical assessment. Follow­up questionnaires 
were also completed face­to­face or by telephone at 
4, 7, and 13 weeks after randomisation by a research 
associate at the recruiting centre. Questionnaires 
were also sent in the post by research associates, or 
collected over the phone by a researcher in the clinical 
trials unit, to optimise follow­up.
The primary outcome was muscle tendon function as 
measured by the validated heel rise endurance test.19 
Participants stood on each leg in turn and raised and 
lowered the heel until fatigued. A computer controlled 
linear encoder (MUSCLELAB, Ergotest Innovation, 
Porsgrunn, Norway) and video recordings collected 
the movement data. The linear encoder measured the 
height of each heel rise, which was used with body 
weight to calculate the work performed by each lower 
limb in joules. Performance was expressed as a limb 
symmetry index (injured limb with rupture/uninjured 
limb measurement×100) for the maximal work done 
during the heel rise endurance test. Two members 
of the study team, masked to treatment allocation, 
independently reviewed all the assessment videos and 
discounted any invalid recordings in the data from the 
heel rise endurance test (supplementary file and fig 
1 provides further information on procedures for the 
heel rise endurance test).
Secondary outcomes were the number of heel 
rise repetitions and maximum heel rise height (cm) 
during the heel rise endurance test at 24 weeks 
after randomisation, patient reported symptoms 
and function (Achilles tendon rupture score 0­100, 
higher score better),20 functional limitation due to 
pain (Achilles tendon rupture score 0­10, higher score 
better; not specified in the protocol but planned before 
completion of follow­up and reported in the published 
statistical analysis plan),16 functional goal attainment 
(patient specific functional scale21 22 0­10, higher 
score better), and health related quality of life (short 
form 12 version 2® (v2) Health Survey, acute version, 
0­100, higher score better)23 at 4, 7, and 13 weeks after 
randomisation. Participants assessed their pain in a 
daily diary using a visual analogue score (0­100, lower 
score better)24 for two weeks after the intervention.
Expected complications, harms, and further 
interventions related to the study treatments were 
recorded as adverse events. Serious adverse events 
were defined as any untoward medical occurrence 
that was both unexpected and related to the study 
treatments that resulted in: death within 30 days of the 
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intervention, death related directly to the intervention 
at any time, life or limb threatening complication, or 
readmission to hospital. Treatment relatedness was 
determined by the site and confirmed by the chief 
investigator.
sample size
The initial sample size target was 214, based on 
detecting a standardised difference of 0.5 at 24 
weeks in the primary outcome (based on data from a 
previous trial where a clinically important difference of 
10% with a standard deviation of 20% from the non­
surgical group was observed at this time point post­
rupture25). The sample size was increased on the data 
monitoring and ethics committees’ advice, based on a 
prespecified masked review of the original sample size 
assumptions (primary outcome standard deviation).15 
16 An initial review on the overall patient population 
(not separated by treatment arm) was undertaken after 
the first 27 participants reached 24 week follow­up, 
at which time the standard deviation was lower than 
assumed. The standard deviation was reassessed 
when 75 patients had reached 24 week follow­up. At 
this point, the standard deviation was greater than the 
original sample size assumption. The sample size was 
therefore recalculated and the recommendation agreed 
with the independent trial steering committee was to 
increase the final sample size to 230 (115 per arm), 
which provided 80% power to detect a standardised 
difference of 0.5 in the work limb symmetry index (as 
measured through the heel rise endurance test) at 24 
weeks after treatment, with 5% (two sided) significance 
and allowing 20% loss to follow­up.
statistical analysis
All participants were included in descriptive analyses. 
The baseline comparability of participant level data 
for each of the treatment groups was summarised and 
treatment compliance explored. Data distributions 
were explored visually using histograms and assess­
ments for normality were carried out using percentile­
percentile plots, quantile­quantile plots, and the 
Shapiro Wilk test. Normally distributed data were 
summarised as means and standard deviations, non­
normally distributed data as medians and interquartile 
ranges, and categorical variables as frequency and 
percentages.
Primary and secondary outcome analyses were 
undertaken on modified intention­to­treat populations: 
all randomised participants with available outcome 
data were analysed in the groups to which they were 
allocated. Multivariable linear regression was used to 
investigate the effect of platelet rich plasma on Achilles 
tendon rupture recovery, adjusting for stratification 
variables and predefined prognostic variables (sex, 
body mass index, and smoking status) selected based 
on previous literature. Following a request from the 
data monitoring and trial steering committees, a 
post hoc analysis was undertaken that additionally 
adjusted for time from injury to injection, because 
participants could have had the injury up to 12 days 
before randomisation. Missing data and sensitivity 
analyses are described in the supplementary file.
We assessed data quality and the effect of the 
treatment received using complier average causal effect 
instead of the planned per protocol analysis. Complier 
average causal effect compares the average outcome 
of compliers in the treatment group with the average 
outcome of potential treatment compliers in the placebo 
group. Unlike a per protocol analysis, this analysis 
ensures that patients who did not receive the treatment 
allocated remain within the analysis, allowing for 
balance of randomisation factors to remain. We 
considered non­compliers to be participants from the 
platelet rich plasma group not receiving the allocated 
intervention or who received prepared platelet rich 
plasma that did not concentrate platelets compared 
with their whole blood. The analysis was repeated 
for the secondary outcome measures from the heel 
rise endurance test (limb symmetry index of heel rise 
repetitions and maximum heel rise height). 
We analysed the patient reported outcome mea­
sures using repeated measures, mixed effects, linear 
regression models, adjusting for stratification variables 
and predefined prognostic variables. Time between the 
10˚ incline box
Linear encoder
Fig 1 | Participant performing the heel rise endurance test
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intervention and outcome measurement was included 
in these models as a random effect factor. A P value less 
than 0.05 was considered indicative of a statistically 
significant difference in all analyses.
Complications were categorised as serious adverse 
events, or foreseeable or unforeseeable adverse 
events. We assessed masking success using the 
James and Bang indices26 27; participants were asked 
after their heel rise endurance test at 24 weeks 
which treatment they believed they had received. 
The correlations between the primary outcome and 
both key blood parameters and platelet properties 
were explored visually and assessed using Pearson’s 
correlation. Analyses were conducted by Stata version 
15.0 (StataCorp, College Station, TX). The trial is 
reported following the CONSORT statement and its 
related extensions.28
Patient and public involvement
Our study protocol was developed following a pilot 
study that engaged with a panel of 75 patient and 
public involvement (PPI) representatives through 
a survey about key aspects of the proposed design. 
Subsequently, we reduced the number of follow­
up contacts with participants. The trial steering 
committee had a PPI representative throughout 
all phases of set­up through to analysis. This PPI 
representative was involved in reviewing patient 
facing materials, including participant questionnaires 
and a presentation graphic to be used in future public 
engagement meetings. The results will be disseminated 
to trial participants, institutional public engagement 
meetings, and more widely through engagement with 
musculoskeletal charities and established national PPI 
networks.
Assessed for eligibility
Excluded
Not meeting eligibility criteria
Eligible patient not approached
Declined to participate
728
108
100
Allocated to platelet rich plasma injection
Received allocated intervention
Patient withdrew
Received placebo
  Venesection unsuccesful
  Centrifuge technical issue
  Participant did not attend
  Disposable kit not available
Completed patient reported outcomes at
  baseline
103
1
10
113
Allocated to placebo injection
Received allocated intervention
Patient withdrew
Received platelet rich plasma injection
Completed patient reported outcomes at
  baseline
116
0
0
116
Lost to follow-up
Completed heel rise endurance test
Completed patient reported outcomes at
  4 weeks
Completed patient reported outcomes at
  7 weeks
Completed patient reported outcomes at
  13 weeks
Completed patient reported outcomes at
  24 weeks
101
111
107
104
109
5
2
1
2
Randomised
936
230
116 114
12
Lost to follow-up
Completed heel rise endurance test
Completed patient reported outcomes at
  4 weeks
Completed patient reported outcomes at
  7 weeks
Completed patient reported outcomes at
  13 weeks
Completed patient reported outcomes at
  24 weeks
101
108
108
104
108
12
Analysed: primary outcome
Excluded
Analysed: secondary outcome
0
109
1166
101
Analysed: primary outcome
Excluded (all repetitions with heel rise
  endurance test deemed invalid at review)
Analysed: secondary outcome
1
107
100
Fig 2 | cOnsOrt diagram
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Recruitment took place from 28 July 2015 to 18 Sep­
tember 2017, with follow­up completed on 9 March 
2018. Of 1166 patients assessed for eligibility, 230 
consented to randomisation (fig 2 and supplementary 
table S1). Baseline characteristics were well matched 
between the randomised groups, one participant in the 
platelet rich plasma group withdrew before completing 
the baseline questionnaire (table 1). Participants were 
on average 46 years old and 57 (25%) were female. 
Missing data accounted for 12% (28/230) of the 
primary outcome data and 6% (14/230) of the patient 
reported outcome data. We analysed 87% (201/230) of 
participants in the primary analysis. One participant’s 
data were excluded owing to invalid measurements.
All of the placebo group (116/116) received their 
allocated treatment. In the platelet rich plasma group, 
one participant withdrew before receiving treatment, 
and 10 (9%) received a placebo injection instead 
of their allocated injection of platelet rich plasma 
because of a technical failure in the delivery of platelet 
rich plasma (fig 2). A consultant surgeon delivered 
the injections for 86 (76%) of the platelet rich plasma 
group and 87 (75%) of the placebo group. Surgical 
registrars or fellows or specialist physiotherapists 
delivered the remaining injections. Injections were 
delivered on average 5.3 (standard deviation 3.0) days 
after injury.
The prepared platelet rich plasma had 4.1­fold 
(95% confidence interval 3.6 to 4.5) greater platelet 
concentrations and 2.2­fold (95% CI 2.0 to 2.5) greater 
leucocyte concentrations than whole blood. Platelet 
quality measurements showed that platelet rich plasma 
was not activated before injection (CD62p expression 
4.3%, standard deviation 5.0%) and was functional 
in vitro (60.1%, 22.3%). Growth factor concentrations 
were: vascular endothelial growth factor 1.0 ng/mL 
(standard deviation 0.7), transforming growth factor 
β1 131.9 ng/mL (74.4), platelet derived growth factor­
AB 55.3 ng/mL (27.6), insulin­like growth factor 1 
78.2 ng/mL (23.2), and fibroblast growth factor­basic 
111.0 pg/mL (77.0).
Venous thromboembolism prophylaxis complied 
with individual hospital protocols and was prescribed 
to half of the participants (platelet rich plasma, 56/113; 
placebo, 58/116). The two groups had similar number 
of days to injured limb weight bearing (platelet rich 
plasma, mean 27 (standard deviation 24); placebo, 28 
table 1 | baseline demographic and clinical characteristics of randomised participants, summarised by treatment group
characteristic Platelet rich plasma (n=113) Placebo (n=116)
Age (mean (SD)) 45.90 (13.74) 45.16 (12.43)
Female (No (%)) 25 (22.12) 32 (27.59)
Body mass index (mean (SD))* 27.69 (5.29) 27.25 (4.22)
Time since injury (days; mean (SD)) 5.35 (2.95) 5.20 (3.08)
Injured during sports participation (No (%)) 81 (71.68) 76 (65.52)
Alcohol consumption (units/week; median (IQR)) 6 (2-12) 8 (2-18)
Smoker (No (%)) 14 (12.39) 13 (11.21)
Achilles tendon rupture score (median (IQR))† 12 (4, 19) 10 (4.5, 16)
Achilles tendon rupture score—functional limitation  
due to pain (median (IQR))‡
3 (0-7) 3 (0-5)
Pain visual analogue score (median (IQR))§ 34 (9-63) 21.50 (9-54)
Patient specific functional score (median (IQR))¶ 3 (0.67-6.67) 3 (1-6.67)
Short form 12 version 2® (median (IQR))**
 Pre-injury physical component 57.01 (50.11-58.05) 57.21 (48.33-58.43)
 Pre-injury mental component 56.38 (50.48-59.05) 56.38 (49.30-59.21)
 Post-injury physical component 30.09 (26.10-34.61) 28.84 (24.40-34.25)
 Post-injury mental component 48.12 (37.75-59.06) 50.55 (41.58-58.85)
No (%) of comorbidities
 0 44 (38.94) 56 (48.28)
 1 36 (31.86) 28 (24.14)
 2 20 (17.70) 23 (19.83)
 >2 13 (11.50) 9 (7.76)
No (%) of drugs affecting platelet function†† 7 (6.19) 8 (6.90)
Whole blood analysis (mean (SD))‡‡
Erythrocytes (×1012/L) 4.83 (0.59) 4.83 (0.48)
Leucocytes (×109/L) 6.74 (2.05) 7.00 (1.90)
Platelets (×109/L) 208.18 (77.73) 227.23 (65.54)
SD=standard deviation; IQR=interquartile range. One participant in the platelet rich plasma group withdrew before completing the baseline 
questionnaire.
*Data were not available for two participants in the placebo group.
†Scores were from 0 to 100, with 0 indicating major limitations and 100 indicating no limitations.
‡Scores were from 0 to 10, with 0 indicating major limitations and 10 indicating no limitations.
§Scores were from 0 to 100, with 0 indicating no pain and 100 indicating worst pain imaginable. Data were available for 93 participants in the platelet 
rich plasma group and 86 in the placebo group.
¶Scores were from 0 to 10, with 0 indicating participants were unable to perform and 10 indicating they were able to perform at the prior level. Data on 
the patient specific functional scale were not available for one participant in the placebo group.
**Scores were from 0 to 100, with higher scores indicating better quality of life.
††Question on drug treatment added during trial recruitment; data available for 81 participants in the platelet rich plasma group and 76 in the placebo 
group.
‡‡Erythrocyte and leucocyte analyses available for 107 participants in the platelet rich plasma group and 114 in the placebo group; platelet analyses 
available for 104 participants in the platelet rich plasma group and 110 in the placebo group.
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(16)) and starting ankle motion exercise (47 (20); 48 
(20)).
We saw no evidence of a difference in muscle tendon 
function between the two groups, measured by the 
maximum work limb symmetry index (adjusted mean 
difference −3.9% (95% confidence interval −10.5% 
to 2.7%; platelet rich plasma, mean 34.7% (standard 
deviation 17.7%); placebo, 38.5% (22.8%); table 2). 
Sensitivity analyses supported the primary analysis 
findings, and results from the analysis for complier 
average causal effect were consistent with these 
conclusions (adjusted mean difference −4.3% (95% 
confidence interval −11.0% to 2.4%), supplementary 
table S2). A post hoc analysis was performed where the 
primary adjusted analysis was also adjusted for time 
from injury to injection. The results for limb symmetry 
index were consistent (adjusted mean difference −3.7% 
(95% confidence interval −10.2% to 2.8%); platelet 
rich plasma, mean 34.9% (standard deviation 16.7%); 
placebo, 38.6% (23.5%)). The James and Bang blinding 
indices indicated no evidence to suggest that masking 
was unsuccessful (supplementary table S3). Neither 
cellular and growth factor concentrations in platelet rich 
plasma nor quality measurements correlated with work 
limb symmetry index except for vascular endothelial 
growth factor (r=−0.23, P=0.03; table 3).
We saw no evidence of any differences between 
the platelet rich plasma and placebo groups in the 
other measures related to the heel rise endurance test 
(maximum heel rise height and heel rise repetitions), 
the patient reported outcomes of the Achilles tendon 
rupture score (fig 3), Achilles tendon rupture pain 
score, patient specific functional scale, or short form 
12v2® at 4, 7, 13, or 24­week follow­up (table 2 and 
supplementary figs S1 to S3), or pain during the two 
weeks after injection (table 2 and supplementary fig 
S4). The two groups had similar adverse event rates 
related to their Achilles rupture or injection (platelet 
table 2 | Primary and secondary outcomes at 7, 14, and 24 week follow-up
Measure and follow-up
Platelet rich plasma Placebo treatment comparison (adjusted 
difference (95% ci))* P valueno Mean (sD) no Mean (sD)
Heel rise endurance test (%; mean (sD))†
Work limb symmetry index 
 24 weeks 100 34.67 (17.66) 101 38.54 (22.82) −3.87 (−10.45 to 2.71) 0.23
Maximum heel rise height, limb symmetry index
 24 weeks 100 55.10 (17.36) 101 55.43 (27.83) −0.35 (−6.09 to 5.38) 0.90
Maximum heel rise repetitions, limb symmetry index
 24 weeks 100 50.08 (30.03) 101 60.75 (37.68) −10.67 (−21.91 to 0.56) 0.06
achilles tendon rupture score
Mean (SD))‡
 4 weeks 107 28.46 (16.76) 109 30.61 (16.23) −2.15 (−6.55 to 2.25) 0.34
 7 weeks 107 37.58 (16.61) 109 38.62 (16.42) −1.04 (−5.45 to 3.37) 0.64
 13 weeks 107 51.66 (16.79) 109 53.11 (16.51) −1.45 (−5.89 to 2.99) 0.52
 24 weeks 107 64.99 (16.48) 109 65.53 (16.17) −0.54 (−4.90 to 3.81) 0.81
Pain component score (mean (SD))§ 
 4 weeks 107 6.26 (2.98) 109 6.28 (2.89) −0.02 (−0.81 to 0.76) 0.95
 7 weeks 107 7.01 (2.96) 109 6.68 (2.93) 0.33 (−0.46 to 1.11) 0.42
 13 weeks 107 7.49 (3.00) 109 7.24 (2.95) 0.25 (−0.54 to 1.05) 0.53
 24 weeks 107 7.66 (2.93) 109 7.45 (2.88) 0.21 (−0.56 to 0.99) 0.59
Patient specific functional score (mean (sD))¶
 4 weeks 107 2.02 (2.18) 109 2.03 (2.12) −0.01 (−0.58 to 0.56) 0.98
 7 weeks 107 3.13 (2.17) 109 3.36 (2.14) −0.23 (−0.80 to 0.35) 0.44
 13 weeks 107 5.81 (2.19) 109 5.78 (2.15) 0.03 (−0.55 to 0.61) 0.91
 24 weeks 107 7.20 (2.16) 109 7.49 (2.12) −0.30 (−0.87 to 0.27) 0.31
short form 12 version 2® (mean (sD))**
Physical component
 4 weeks 105 38.87 (7.78) 108 39.00 (7.62) −0.14 (−2.21 to 1.93) 0.90
 7 weeks 105 40.73 (7.75) 108 42.42 (7.69) −1.69 (−3.77 to 0.39) 0.11
 13 weeks 105 45.76 (7.84) 108 46.27 (7.74) −0.51 (−2.61 to 1.58) 0.63
 24 weeks 105 50.24 (7.78) 108 49.44 (7.64) 0.80 (−1.27 to 2.88) 0.45
Mental component
 4 weeks 105 48.29 (9.55) 108 50.69 (9.34) −2.40 (−4.94 to 0.14) 0.06
 7 weeks 105 52.05 (9.51) 108 53.42 (9.44) −1.37 (−3.91 to 1.18) 0.29
 13 weeks 105 56.42 (9.60) 108 55.67 (9.48) 0.74 (−1.82 to 3.30) 0.57
 24 weeks 105 53.79 (9.49) 108 55.60 (9.32) −2.71 (−5.24 to −0.19) 0.04
Pain visual analogue score (mean (sD))††
14 days 93 9.55 (21.45) 87 13.57 (21.51) −4.02 (−10.30 to 2.26) 0.21
SD=standard deviation.
*Differences adjusted for age category (<55 v ≥55 years) and clustered by study site.
†Scores were injured/uninjured value×100, with 0 indicating no symmetry and 100 indicating perfect symmetry between limbs.
‡Scores were from 0 to 100, with 0 indicating major limitations and 100 indicating no limitations.
§Scores were from 0 to 10, with 0 indicating major limitations and 10 indicating no limitations.
¶Scores were from 0 to 10, with 0 indicating participants were unable to perform and 10 indicating they were able to perform at the prior level.
**Scores were from 0 to 100, with 0 indicating worst and 100 indicating best. Differences further adjusted to account for participants pre-injury score.
††Scores were from 0 to 100, with 0 indicating no pain and 100 indicating participants’ perceived worst pain imaginable.
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rich plasma, 84/113 (74%); placebo, 90/116 (78%) 
participants reporting at least one complication 
related to their Achilles rupture or injection; table 4). 
Re­rupture rates were 5% (6/113) in the platelet rich 
plasma group and 3% (4/116) for the placebo group, 
of whom nine participants went on to have surgical 
treatment. Rates of deep vein thrombosis were 5% 
(6/113) in the platelet rich plasma group and 4% 
(5/116) in the placebo group. One serious adverse 
event, an ST elevation myocardial infarction, occurred 
2.5 hours after platelet rich plasma injection, which 
was deemed indirectly plausible.
discussion
Principal findings
This large randomised controlled trial found no 
evidence that platelet rich plasma injections improved 
muscle tendon function, patient reported function, 
pain, goal attainment, or quality of life in patients 
with acute Achilles tendon rupture. The hypothesised 
benefits of platelet rich plasma in tendon injury 
healing, based on encouraging findings in laboratory 
studies, did not translate into a detectable patient 
benefit. Our use of a standardised device for platelet 
rich plasma preparation, quality control procedures 
across 19 hospitals, and robust trial design and 
conduct strengthen the confidence in our findings.
We used outcomes based on the main limitations 
people experience after an acute tendon rupture. 
Muscle tendon function was selected as the primary 
outcome measure because this is the primary 
impairment after Achilles tendon rupture and can be 
quantitatively assessed. We also used the validated 
patient reported outcome (Achilles tendon rupture 
score),29 because we recognised that platelet rich 
plasma could have wider effects on patients’ recovery 
experience. The consistency and precision in the 
estimates indicated no evidence of platelet rich plasma 
efficacy in any of the assessed outcomes. The finding 
of the PATH­2 trial highlights that the use of platelet 
rich plasma preparations in soft tissue injuries must 
be questioned unless supported by robust evidence 
indicating positive outcomes.
comparison with other studies
Systematic reviews have synthesised evidence from 
37 clinical trials on platelet rich plasma applications 
in musculoskeletal injuries so far.10 11 Comparisons 
with our study are challenging owing to heterogeneity 
in clinical applications, lack of standardisation of 
platelet rich plasma preparations and quality controls, 
underpowered studies, and potential confounders such 
as concurrent surgery in those trials. Achilles ruptures 
are increasingly being treated non­surgically,30 but 
previous trials of platelet rich plasma in Achilles 
tendon rupture have used platelet rich plasma as an 
adjunct to surgical repair, and have low statistical 
power and high loss to follow­up.12 13
strengths and limitations of the study
To our knowledge, PATH­2 was the largest trial so far 
to investigate the efficacy of platelet rich plasma in 
acute tendon ruptures. The interventions were embed­
ded into usual care pathways, which enhances the 
generalisability of the findings. Platelet rich plasma 
analysis indicated that our preparation method pro­
duced a leucocyte and platelet rich plasma of optimal 
quality that would have provided a supraphysiological 
concentration of leucocytes and platelets capable of 
degranulating and releasing high concentrations of 
growth factors on injection, with few exceptions.
Platelet rich plasma preparations are often poorly 
reported and not standardised between trials, leading 
to heterogeneity and uncertainty in the literature.31 
These preparations could contain supraphysiological 
or subphysiological concentrations of leucocytes. The 
effects of leucocytes in platelet rich plasma for tendon 
healing are uncertain, with in vitro investigations 
identifying both potential benefits and limitations 
at the cellular level.32 Currently, leucocyte rich 
preparations are commonplace in clinical practice, 
as buffy­coat­derived platelet rich plasma results 
in substantial leucocyte and red cell inclusion. In 
PATH­2, we used a method to prepare leucocyte and 
platelet rich plasma that had cellular and growth 
table 3 | correlation assessment between primary outcome and key blood parameters 
and platelet and growth factor properties in samples of platelet rich plasma
Key blood parameters and platelet properties no r variance (%)* P value
blood cell counts
Erythrocyte count 91 0.13 1.59 0.23
Leucocyte count 91 −0.10 1.05 0.33
Platelet count† 88 0.13 1.65 0.23
Platelet quality (resting)
Resting CD62p expression (%) 93 0.10 0.92 0.75
Mean fluorescence intensity 94 −0.03 0.07 0.97
Platelet quality (activated)
Activated CD62p expression (%) 92 0.04 0.14 0.72
Mean fluorescence intensity 92 <−0.01 <0.01 0.97
growth factors
Insulin-like growth factor 1 93 0.12 1.25 0.29
Transforming growth factor β1 88 0.01 <0.01 0.96
Platelet derived growth factor-AB 90 <0.01 <0.01 1.00
Vascular endothelial growth factor 93 −0.23 5.35 0.03
Fibroblast growth factor-basic 93 −0.10 1.05 0.33
CD62p=P selectin.
*Proportion of variance in work limb symmetry index explained by blood parameter.
†As fluorescent platelet count.
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Fig 3 | results from repeated measures, mixed effects regression model, showing 
change in achilles tendon rupture score in study participants (receiving platelet rich 
plasma v placebo) over time. bars=95% confidence intervals
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factor levels consistent with the preparation device 
manufacturer’s specifications33 and those observed 
within other controlled laboratory studies of healthy 
individuals.34­36 Unlike many previous trials,37 we fully 
defined what the participants received and importantly 
found no correlation between any platelet or leucocyte 
parameters of platelet rich plasma and muscle tendon 
function outcome. We also did not see a correlation 
between growth factors and muscle tendon function 
outcome, except for a weak negative correlation with 
vascular endothelial growth factor. The analysis on 
complier average causal effect had similar findings 
to the primary analysis, indicating that observed 
deficiencies in adhering to the intervention protocol 
did not affect the final results.
The PATH­2 trial had some limitations. Different 
volumes of whole blood were taken from the two 
randomisation groups (55 mL platelet rich plasma v 5 
mL placebo). Despite safeguards, participant masking 
could have been compromised. However, indices used 
to measure participant masking after assessment of the 
primary outcome indicated that participants did not 
accurately predict their allocated treatment. Although 
the rehabilitation protocol set boundaries on the 
length of immobilisation and weight bearing, variation 
is still possible in these factors and in the content of 
the physiotherapy sessions. However, time to weight 
bearing, duration of immobilisation, and referral rates 
to physiotherapy were balanced between the groups, 
and centre effects were managed with stratification 
and adjustment of estimates.
conclusions and policy implications
We found no evidence that, compared with placebo, 
platelet rich plasma injections have an effect on 
objective muscle tendon function, patient reported 
function, or quality of life after acute Achilles tendon 
rupture, indicating that platelet rich plasma offers no 
patient benefit.
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table 4 | treatment related adverse events during study. Data are the number of participants (%) experiencing event
Platelet rich plasma group (n=113) Placebo (n=116)
Participants experiencing at least one adverse event of any type* 84 (74.34) 90 (77.59)
serious adverse events* 1 (0.88) 0
 ST elevation myocardial infarction 1 (0.88) 0
adverse events* 84 (74.34) 90 (77.59)
Foreseeable adverse events* 83 (73.45) 87 (75.00)
 Mild discomfort or minor bleeding following injection 22 (19.47) 8 (6.90)
 Technical complications of lower leg casting and splinting 38 (33.63) 28 (24.14)
 Consequences of depending on walking aids 1 (0.88) 1 (0.86)
 Syncopal episode related to venesection or tendon injection 0 0
 Discomfort at rupture site during rehabilitation 9 (7.96) 10 (8.62)
 Swelling or bruising of the lower leg and foot 68 (60.18) 77 (66.38)
 Deep vein thrombosis in a lower limb 6 (5.31) 5 (4.31)
 Re-rupture of treated Achilles tendon 6 (5.31) 4 (3.45)
Unforeseeable adverse events* 16 (14.16) 19 (16.38)
 Serious infection of injection site of Achilles tendon rupture 0 0
 Skin breakdown or ulceration of treated lower leg 13 (11.50) 13 (11.21)
 Severe pain (more than simple analgesia) >10 days after injection 6 (5.31) 6 (5.17)
Other adverse events related to treatment or Achilles tendon rupture* 13 (11.50) 13 (11.21)
 Frequent discomfort at injection site 5 (4.42) 6 (5.17)
 Infection at injection site confirmed by doctor 0 3 (2.59)
 Infection at non-injection site† 0 3 (2.59)
 Other problem‡ 9 (7.96) 6 (5.17)
*Participants could have experienced multiple adverse events so number of participants reporting foreseeable and unforeseeable adverse events may not 
add up to the overall total reporting.
†Infections included cellulitis, pneumonia, and an infected insect bite on the treated leg.
‡Participant specific complications associated with treatment or rupture not covered by other complication types.
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